| Title: |
Sociodemographic and clinicopathologic characteristics of patients treated with high dose rate prostate brachytherapy in Nigeria. |
| Authors: |
Abdus-Salam, Abbas A.1 adrusa@gmail.com, Jimoh, Mutiu A.1, Folasire, Ayorinde M.1, Ntekim, Atara I.1, Ojo, Olabisi T.2, Ehiedu, Chiamaka G.2, Yusuf, Sikiru A.2, Takure, Augustine O.3, Akinlade, Bidemi I.1, Idowu, Olusola K.4, Oladeji, Afolabi A.1, Sarimiye, Foluke O.1, Adenipekun, Adeniyi A.1 |
| Source: |
Ecancermedicalscience. 2024, Vol. 18 Issue 1706-1753, p1-17. 17p. |
| Subject Terms: |
*HIGH dose rate brachytherapy, *CLINICAL pathology |
| Abstract (English): |
This document is a compilation of various research studies and articles on prostate cancer, focusing on treatment approaches, patient characteristics, and outcomes. The studies cover countries such as Nigeria, Ghana, Burkina Faso, and Cameroon, and examine factors like marital status, socioeconomic status, and age in relation to prostate cancer. The document provides valuable information for researchers and healthcare professionals interested in understanding the diverse perspectives and experiences of prostate cancer patients in different regions. [Extracted from the article] |
| Abstract (Abkhazian): |
Introduction: Prostate cancer is the most commonly diagnosed malignancy in adult males. High dose rate brachytherapy (HDRB) recently became available in the country for the management of localized prostate cancer in addition to other treatment modalities. HDRB offers a less invasive option to radical prostatectomy and also has a better side effects profile. Aim: To report the socio-demographic features of the patients treated with HDRB, the clinicopathologic pattern of their disease and possible predictors of these features. Methods: A retrospective study of patients with histopathologically confirmed prostate cancer, who had HDRB at the Department of Radiation Oncology, University College Hospital, Ibadan, Nigeria, between July 2020 and 2023 was done. Patients' socio-demographic and clinicopathologic characteristics were extracted from their treatment records. Results: A total of 73 patients had HDRB within the period under review. The median age was 66 years (51-78 years). About 40% had prostate cancer diagnosed following routine prostate-specific antigen (PSA) screening. The median screening PSA was 20.5 ng/mL (5.83-75.35 ng/mL). About a quarter (24.7%) were asymptomatic at presentation while frequency (60.3%), nocturia (45.2%) and urgency (35.6%) were the most common symptoms. The median initial PSA was 26.00 ng/mL (5.10-124.50 ng/mL) and the median PSA before brachytherapy was 6.25 ng/mL (0.03-175.30 ng/mL), the majority (75.3%) had androgen deprivation therapy before brachytherapy. Forty-seven patients (64.4%) presented with TNM stages 1 and 2 while grade group 2 (24.7%) and high risk (76.7%) were the commonest grade group and risk group, respectively. There was a significant association between age group and TNM stage (p = 0.043), level of education (LOE) and TNM stage (p = 0.037) as well as PSA screening and grade group (p = 0.007). Conclusion: The majority of the patients who presented for prostate brachytherapy were elderly, had higher initial PSA, were in the high-risk group and had early-stage disease. About 25% of the patients were asymptomatic at presentation. Patients with tertiary LOE and elderly patients presented more with stage 1 and 2 diseases. [ABSTRACT FROM AUTHOR] |
|
Copyright of Ecancermedicalscience is the property of Cancer Intelligence and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
